Updated October 20th, 2021 at 10:17 IST
WHO Chief discusses Covaxin EUL with Health minister Mansukh Mandaviya
World Health Organisation (WHO) Chief on Tuesday held a telephonic conversation with Union Health Minister Mandaviya discussing the Emergency Use Listing.
Advertisement
World Health Organisation (WHO) Chief on Tuesday held a telephonic conversation with Union Health Minister Mansukh Mandaviya discussing the Emergency Use Listing (EUL) of Covaxin. While reports of the global body giving a green signal to the domestically developed COVID vaccine have been circulating for a few days now, the recent conversation marks a concrete step towards its much-awaited approval. Earlier this week, WHO had informed that the vaccine's manufacturer, Indian pharma major Bharat Biotech has been submitting data on a rolling basis along with additional information following a WHO request on September 27.
Vaccine Equity
In a tweet, Tedros Adhanom Ghebreyesus said he also deliberated upon India’s ongoing COVID vaccination program and the need for a ‘global pandemic agreement’. Additionally, they both also talked about new-age digital health, traditional medicine as well as global vaccine equity. Ghebreyesus also lauded the Modi administration’s support to strengthen WHO via its contribution to the COVAX initiative, flexibility, technology sharing and sustainable financing.
“The Minister and I also discussed #VaccinEquity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP,” he said.
Had a call with @mansukhmandviya, 🇮🇳 Health Minister, to discuss #India's ongoing #COVID19 vaccination program; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome 🇮🇳's support to strengthen WHO, incl. via flexible, sustainable financing. pic.twitter.com/XhCVIhZBIe
— Tedros Adhanom Ghebreyesus (@DrTedros) October 19, 2021
Image: AP/PTI
Advertisement
Published October 20th, 2021 at 10:17 IST
Your Voice. Now Direct.
Send us your views, we’ll publish them. This section is moderated.